Remove 2021 Remove Drug Development Remove Remote care
article thumbnail

Where are HealthTech's soft landing M&A deals in today's market?

Lloyd Price

Market Dynamics: Lower valuations: Compared to the heady days of 2021, HealthTech valuations have cooled down, making "soft landing" deals more attractive for both acquirers and targets. Pharmaceutical and Life Sciences Companies: These companies are looking for HealthTech solutions to: Enhance clinical trials and drug development processes.

article thumbnail

The outlook for healthcare in 2022

Waracle

2021 has been a historic year for healthcare… and technology has been a crucial piece of the puzzle when it comes to keeping the healthcare industry resilient in the face of the challenges it has seen. . But that was 2021, what about the new year.? Prioritising remote care and wellness.